While the Canadian Cardiovascular Society’s lipid guidelines recommend a once in a lifetime testing of Lp(a), there are no approved agents for lowering Lp(a) levels.
Canadian Rheumatology Association issues best practice statements and recommendation for choosing DMARD therapy after an inadequate response to TNF inhibitors.